Link Cell Therapies develops advanced CAR T cell therapies utilizing an AND-gate logic system for enhanced specificity in cancer treatment. The company focuses on engineering these cell therapies to target both solid and liquid tumors effectively. Their platform aims to improve the therapeutic window and safety profile of adoptive cell transfer approaches.
Funding
$12M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
CAR T-cell therapies have shown promise in treating hematologic cancers, but their application to solid tumors is limited by off-target toxicities due to the expression of target antigens on healthy tissues. Existing logic-gate technologies do not provide sufficient specificity to safely deploy CAR T-cells against solid tumors.
Solution
Link Cell Therapies is developing AND-gate CAR T-cell therapies that require the co-expression of two cancer-specific target antigens to trigger cell cytotoxicity, enhancing specificity and reducing off-tumor toxicity. This dual-targeting approach aims to improve the safety profile of CAR T-cell therapies, enabling their application to a broader range of cancers, including solid tumors and certain hematologic malignancies. The company's technology platform is designed to unlock the potential of CAR T-cell therapy across multiple cancer indications by precisely targeting tumor cells while sparing healthy tissue. By requiring the presence of two distinct antigens, Link Cell Therapies' AND-gate CAR T-cells minimize the risk of unintended damage to normal cells, potentially leading to better patient outcomes.
Target Audience
The primary target audience includes patients with solid tumors and specific hematologic cancers who are eligible for CAR T-cell therapy, as well as clinicians and researchers in the field of oncology and cell therapy.
Features
- AND-gate CAR T-cell design requiring co-expression of two cancer targets for activation
- Enhanced specificity to minimize off-target toxicity in solid tumors
- Novel logic-gate technology for precise targeting of tumor cells
- Development of CAR T-cell therapies for both solid tumors and hematologic cancers
- Platform technologies to improve the efficacy of CAR T-cells in solid tumors and overcome therapeutic resistance